Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 29, 2022

Primary Completion Date

April 2, 2026

Study Completion Date

April 2, 2026

Conditions

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Decitabine

Given IV

BIOLOGICAL

Navitoclax

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER